Tirzepatide Research for Weight Loss
An evidence-based overview of research examining Tirzepatide in the context of weight loss. This page synthesizes findings from peer-reviewed literature.
Research Summary
Tirzepatide produced substantial weight loss in the SURMOUNT trials. SURMOUNT-1 showed 20.9% mean weight loss at the highest dose (15mg) versus 3.1% with placebo at 72 weeks (N=2,539). Tirzepatide activates GIP and GLP-1 receptors, but the separate contribution of each receptor to clinical weight loss is not established. The head-to-head SURMOUNT-5 trial showed tirzepatide achieved 20.2% weight loss versus 13.7% for semaglutide at 72 weeks. In SURMOUNT-1, 57% of participants on the 15mg dose achieved 20% or greater weight loss. FDA approval for chronic weight management (Zepbound) came in November 2023.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.